Vaubel, Rachael A.

Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma

Vaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 227

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

Kim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentBarrier Structure and Function Studies

Cited by 39

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 8

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)

Sarkaria, J. N., Mrugala, M. M., Jaeckle, K. A., Burns, T. C., Vaubel, R. A., Parney, I. F., Chaichana, K., Clement, P. M., Martinez-Garcia, M., Sepulveda Sanchez, J. M., et al. (2024) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 3

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 2

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 0